Creatine's depression promise split: 2 trials helped, 3 showed no benefit in review

Creatine is best known as a muscle-building supplement, but a new review suggests the story for depression is messier than marketers would like. Scientists examined five randomized clinical trials involving 238 participants to test whether creatine could help treat depression by boosting the brain's energy supply. The headline result: mixed outcomes. In two studies, adding creatine to standard treatment improved depressive symptoms. In the other three studies, there was no meaningful benefit.

The split is not subtle in terms of who was studied and what happened. The two positive trials both involved women with major depressive disorder. In those trials, creatine was used alongside standard treatment, and symptoms improved. The three other trials, also included in the same review, did not find a meaningful benefit from adding creatine. That detail matters because it hints at possible differences in populations, study designs, baseline biology, or how depression was measured. Whatever the reason, the clinical signal is not uniform.

Why this is interesting now is because depression treatments are a crowded, expensive ecosystem where “maybe it helps” can still drive real money, real trials, and real regulatory risk. Creatine sits at an unusual intersection. It is widely recognized as a supplement, which generally means it is sold and discussed through a consumer lens. Yet this review frames the mechanism in clinical terms: creatine may help fight depression by boosting the brain's energy supply. That is a different pitch than “more muscle.” It is also the kind of biological plausibility that attracts researchers and companies alike, because it can justify investment even before large, definitive phase results land.

This is also the kind of evidence that can create board-level confusion. Mixed results force leaders to answer an uncomfortable question: is the opportunity real but narrow, or is it a false start? In investment and product strategy, the difference between those two interpretations changes everything. If benefits concentrate in specific groups, then the path forward may require targeted clinical development, subgroup analysis, or carefully designed follow-up trials. If benefits do not replicate, then spending further capital becomes harder to defend. The review does not resolve that debate, but it does surface the core tension: two studies showed improvement, three did not.

There is a practical regulatory angle here too, even though the source does not dive into agency decisions. In general, claims about treating depression raise the stakes far beyond supplement language. Moving from “supports wellness” to “treats depression” typically requires medical evidence that is stronger and more consistent than what a handful of small randomized trials can provide. When the evidence is mixed, regulators, clinicians, and payers tend to demand clarity. That means any organization thinking about creatine as a depression intervention will likely need to treat this review as early signal, not as a license to market.

For executives, the second-order implication is that creatine's depression narrative may behave like a “platform” story, but with uncertainty baked in. The mechanism hypothesis, involving the brain's energy supply, is the kind of idea that can be explored across multiple conditions. But the actual clinical outcomes in this review do not neatly support broad, universal use. So even if the mechanism remains compelling, the commercial and clinical strategy may need to be more surgical than a generic “add creatine for mood” pitch.

What should peers take from this? The review's design is a clue. It looked at five randomized clinical trials and 238 participants, which is a meaningful slice of existing research, but it is still not the same thing as one definitive trial. Mixed results across randomized studies are a real pattern, not a fluke of observational data. That makes it more likely that the next phase will focus on reducing variability: who gets the intervention, how depression is defined, what outcome metrics are used, and how long supplementation lasts.

In plain terms, creatine is not a slam dunk for depression based on this review. Two trials in women with major depressive disorder reported that adding creatine to standard treatment improved symptoms. Three other trials found no meaningful benefit. For decision-makers, that is the kind of evidence you can build on, but not the kind you can ignore. The strategic stakes are straightforward: the organizations that move thoughtfully will align research and product ambitions with a reality that is currently split, not settled.